SYBX vs VRTX · P/E 5.5, $14.2M cap vs P/E 30, rev $3.33B
Synlogic Inc (SYBX) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Synlogic Inc (SYBX) is a biotechnology company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Latest reported SYBX revenue for 2026-06-30 was $0. Net income was -$543.0K. SYBX currently screens at market cap $14.2M and trailing P/E 5.5.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
SYBX currently screens at market cap $14.2M and trailing P/E 5.5. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the SYBX and VRTX stock pages for the full models.
Not investment advice.